Congenital Adrenal Hyperplasia (CAH) Pediatric Profile 6, Comprehensive Screen
Use
This test is designed to provide a comprehensive screening for Congenital Adrenal Hyperplasia (CAH) in pediatric patients. It measures a panel of adrenal steroids that are typically altered in CAH, allowing for the detection and monitoring of steroid hormone imbalances associated with CAH. This is critical for the management and treatment planning of patients affected by the condition, as CAH can lead to ambiguous genitalia, early puberty, and in severe cases, life-threatening adrenal crises.
Special Instructions
To avoid delays in turnaround time when requesting multiple tests, submit separate frozen specimens for each test requested.
Limitations
The test has not been cleared or approved by the FDA, as it was developed and performance characteristics determined by LabCorp. Gross hemolysis, lipemia, or icteric samples may cause rejection and impact test validity. Minimum volume submitted does not allow for repeat testing, which may affect outcomes in necessary retesting scenarios.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 2143-6
- 1656-8
- 1657-6
- 2193-1
- 6765-2
- 2839-9
- 1668-3
- 1854-9
- 2986-8
Result Turnaround Time
10-19 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3.5 mL
Minimum Volume
2 mL
Container
Plastic vial
Collection Instructions
Within 45 minutes of collection, centrifuge and aliquot serum into a plastic vial. Send frozen.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icteric
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 90 days |